Actively Recruiting
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
Led by Third Affiliated Hospital, Sun Yat-Sen University · Updated on 2024-11-29
150
Participants Needed
1
Research Sites
305 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to investigate the clinical efficacy of three types of nucleotide/nucleoside analogues in treatment of HBV-related acute-on-chronic liver failure.
CONDITIONS
Official Title
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Positive hepatitis B surface antigen or hepatitis B virus DNA for more than 0.5 year
- Age between 12 and 65 years old
- Serum total bilirubin level greater than 10 times the upper limit of normal
- Prothrombin time activity less than 40% or prothrombin time international ratio greater than 1.5
- No nucleotide/nucleoside analogue treatment in the past 6 months
You will not qualify if you...
- Other active liver diseases
- Hepatocellular carcinoma or other malignancies
- Pregnancy or lactation
- HIV infection or congenital immune deficiency diseases
- Severe diabetes or autoimmune diseases
- Other significant organ dysfunctions
- Current use of glucocorticoids
- Inability to follow up
- Investigator judgment of inappropriate participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630
Actively Recruiting
Research Team
W
Wenxiong Xu, Doctor
CONTACT
L
Liang Peng, Doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here